Hierarchical cell state models, wherein a few stem-like tumor-propagating cells repopulate the tumor after therapy, are often invoked in cancer. Suvà et al. demonstrate a plastic developmental hierarchy in glioma cell populations by characterizing the epigenetic states of phenotypically distinct cells and identifying four factors sufficient to reprogram differentiated cells into a tumorigenic stem-like state.
Solid tumors are heterogeneous masses with various tumor stroma components as well as subpopulations of bona fide tumor cells caused by the parallel evolution of genetically distinct subclones. This branching evolution is typically considered as a unidirectional process, driven by stepwise accumulation of additional genetic alterations. In contrast, the epigenome represents a more dynamic/ multidirectional state that enables cells to adapt to different conditions, allowing for morphological and functional differences within genetically identical cell populations. This functional flexibility is of key importance for the cancer stem cell concept, in which a small subpopulation of tumor-propagating cells with stem cell-like features spawns progeny that undergo a transient expansion and then ''pseudo-differentiation'' to form the tumor bulk (reviewed in Kreso and Dick [2014] ). In glioblastoma (GBM), these cancer stem cells were identified a decade ago (Singh et al., 2004) , and their phenotypical characterization has since been refined. It is not definitively clear, however, whether this ''stemness'' is intrinsic to the early tumor cells or is acquired during tumor development, and the underlying molecular mechanisms behind this plasticity have also remained largely obscure.
In this issue of Cell, Suvà et al. (2014) report on the identification of four transcription factors that can reprogram differentiated tumor cells into stem-like tumor-propagating cells using combinatorial mapping of differential epigenetic marks and gene expression data from these distinct cell populations.
By culturing freshly harvested GBM specimens in different conditions (serum free, spherogenic versus monolayers with serum), the authors describe two different cell populations-stem-like tumor-propagating cells (TPCs) and differentiated GBM cells (DGCs), respectively. TPCs were enriched for postulated stem cell markers such as CD133 (Singh et al., 2004) and are tumorigenic in vivo when as few as 50 cells are transplanted. Epigenetic profiling for the active enhancer mark, H3K27Ac, revealed many loci that are specific to either TPCs or DGCs, with enrichment for certain transcription factor (TF) binding motifs. Further integration with gene expression data highlighted 19 development TFs as being specifically upregulated in TPCs.
Comprehensive combinatorial analysis of the effects of introducing these factors in vitro led to the identification of four core TFs, POU3F2, SALL2, SOX2, and OLIG2, which are sufficient to reprogram DGCs into spherogenic, tumorigenic, induced TPCs (iTPCs; Figure 1 ). In contrast, three-factor combinations were not able to generate iTPCs. The observed phenotypic switch was accompanied by stable epigenetic reprogramming to a stem-like state, which also led to induction of expression of the four factors from endogenous loci.
Although each factor individually was quite widely expressed in primary tumor material, coexpression of this quadrumvirate of ''stemness'' factors was observed in only 2%-7% of cells. This subset was also found to be strongly enriched for CD133 positivity-a marker previously associated with therapy resistance in a native tumor setting (Bao et al., 2006) . Whether reprogramming of bulk cells to a TPC state may also contribute to chemoresistance and tumor recurrence is not yet clear.
Finally, by analyzing core nodes in the transcriptional network controlled by these factors, the authors highlight a regulatory role for a chromatin-modifying complex involving RCOR2 and LSD1. Treatment with an LSD1 inhibitor specifically killed TPCs, but not DGCs or cultured normal astrocytes, whereas LSD1 knockdown dramatically reduced the in vivo tumorigenicity of TPCs. The prospect of targeting both the tumor bulk and the stem cell compartment may therefore be one step closer to realization and could carry the advantage of eliminating tumor-repopulating cells, as well as potentially blocking dedifferentiation of DGCs.
The data presented by the authors offer exciting new insights into tumor evolutionary hierarchies within GBM and also lay the foundation for further investigation into the nature of different subpopulations. Although this study does not disprove the differentiation model of the cancer stem cell hypothesis, it suggests that, at least in this experimental system, there is potential for bidirectional plasticity through epigenetic reprogramming rather than a unidirectional hierarchy between TPCs and DGCs. Additional molecular analysis of TPCs extracted from primary material, through cell sorting for the four TFs, for example, would be of particular interest in assessing the wider relevance of this model. Likewise, assessing the effects of the iTPC factors on classical longterm established monolayer cultures may also provide information as to the extent of reprogrammability even after substantial in vitro adaptation.
One further remaining question highlighted by the authors is the applicability of this model and the TPC-inducing factors across different molecular subtypes of GBM (Brennan et al., 2013; Sturm et al., 2014) . All of the tumors in the present study were of the proneural class, and it would therefore be of interest to determine whether the same or alternative factors would be sufficient to reprogram other groups. Of particular interest in this context is a GBM subtype enriched in teenagers and young adults, harboring a G34R/V substitution in histone H3.3. This group is unusual for GBMs in that it completely lacks expression of OLIG2 (Sturm et al., 2012) , one of the four factors described by Suvà et al. (2014) , suggesting that this is not always essential for GBM tumorigenesis.
One might also wonder whether the four iTPC factors influence differentiated neural cells, and if so, whether a potentially normal stem cell program could be hijacked in tumor cells. Indeed, other studies have described tumor induction through dedifferentiation of neural cells (Friedmann-Morvinski et al., 2012) . In this context, the question again emerges as to whether this epigenetic program is an intrinsic property in a normal cell population preceding transforming mutation(s) or whether it can be acquired stochastically or induced by extrinsic factors (e.g., mutations or microenvironmental cues) over the course of tumor development.
A link between cancer and normal stem cells in glioblastoma has previously been investigated by Stricker et al. (2013) . In that study, the authors applied a subset of reprogramming factors used in production of induced pluripotent stem cells (iPSCs) (Takahashi and Yamanaka, 2006) to reprogram genetically aberrant glioma TPCs. Global DNA methylation patterns were reset, and the treated cells were endowed with a capacity to differentiate into a number of different lineages that remained capable of inducing tumors in vivo, suggesting a dominance of oncogenic alterations over a nonmalignant epigenetic state in this setting. This tumorigenic capacity stands in contrast to the largely nontumorigenic DGCs of the present study; thus, further comparisons of the properties of these cell states, the relationship between putative TPC populations and the multiple genetic subclones in a given tumor, and the details of the epigenetic reprogramming induced by different TF combinations will be of importance both for our understanding of phenotypic plasticity in cancer cells and the interaction between genetic mutations and the dynamic tumor epigenome.
The cancer stem cell hypothesis has led to important insights into our understanding of tumor evolution and phenotypic heterogeneity but also raises many questions about the dynamics of the proposed cellular hierarchy as well as the relationship between tumor-propagating cells and true stem cells. Suvà et al. (2014) integrate large-scale genomics with substantial functional analysis, thereby shedding light on differences between stem-like and differentiated GBM cells and their interconvertibility, as well as raising the possibility of novel targeted therapeutic approaches. Four TFs capable of reprogramming DGCs into TPCs were identified using comprehensive epigenetic mapping and gene expression analysis in glioblastoma cells cultured in serum-containing versus spherogenic, serum-deprived culture conditions and subsequent integrative analysis. Introduction of these four TFs into DGCs was sufficient to induce stemness features and tumorigenic potential. Further investigation of the components downstream of OLIG2 identified LSD1 as a molecular target mediating the reprogramming that is necessary for TPC survival. Treatment with a specific LSD1 inhibitor reduced survival and self-renewal of TPCs.
